Madrigal Pharmaceuticals MDGL reported a fourth-quarter 2025 loss of $2.57 per share, in contrast to the Zacks Consensus ...

Fourth-quarter and full-year 2025 Rezdiffra® (resmetirom) net sales of $321.1 million and $958.4 million, respectively As of year-end 2025, more ...

Reported steady patient growth, ending Q4 2025 with over 36,250 patients, driven by high prescriber confidence and real-world ...

Company advances its leadership in MASH with an expanded pipeline, which now includes more than 10 programs at multiple ...

Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today ...

POWHATAN, Va. ( WWBT /Gray News) - A Virginia grandfather received a life-saving donation from a family member: his ...

Madrigal Pharmaceuticals MDGL announced an exclusive global licensing agreement with Suzhou Ribo Life Science Co. Ltd. (Ribo) ...

Ribo and Ribocure enter exclusive global licensing agreement with Madrigal for novel siRNA therapeutics targeting MASH: Suzhou, China Thursday, February 12, 2026, 15:00 Hrs [IST] ...

Unmet needs in hepatology continue to evolve globally. While the burden of chronic viral hepatitis continues to decline due to improved treatment and prevention, steatotic liver disease is emerging as ...

What is fatty liver disease? The most common liver disorder in the United States, nonalcoholic fatty liver disease (NAFLD) is an accumulation of excess fat in liver cells, taking up 5 to 10 percent of ...

SUZHOU, China and MÖLNDAL, Sweden, Feb. 11, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today announced ...

Company advances its leadership in MASH with an expanded pipeline, which now includes more than 10 programs at multiple stages of development, anchored by Rezdiffra- (resmetirom) as the foundational ...